Skip to main content
SpringerLink
Log in

China as a Growing Research Base for Innovation in Medicines Development

  • Special Section on Medicines Development in China
  • Focus on China
  • Published:
International Journal of Pharmaceutical Medicine Aims and scope Submit manuscript

Abstract

In the current context of China’s rapidly growing economy, multinational drug companies are investing significantly in research and development in China, a trend that has accelerated over the last 10 years. A robust regulatory framework, an abundance of highly equipped medical universities and large patient numbers in all therapy areas make China an increasingly attractive location to conduct clinical research. In addition, data from China are now accepted for inclusion in applications for market authorisation by regulatory agencies worldwide, including the Food and Drug Administration (FDA) in the US. Hence China is becoming an equal partner in global clinical development, a trend that is likely to grow significantly in the years to come.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Table I
Table II

Similar content being viewed by others

References

  1. von Zedtwitz M. Managing foreign R and D laboratories in China. R D Manage 2004; 34 (4): 439–52

    Article  Google Scholar 

  2. Fisher WA, von Zedtwitz M. Chinese R and D: naissance, renaissance or mirage? R D Manage 2004; 34 (4): 349–65

    Article  Google Scholar 

  3. Good clinical practice (SFDA order No. 3). Effective 2003 Sep 1 [online]. Available from URL: http://www.sfda.gov.cn [Accessed 2006 Sep 8]

  4. Regulations for the Administration of Adverse Drug Reaction Reports and Monitoring (SFDA & MOH order No. 7). Effective 2003 Mar 4 [online]. Available from URL: http://www.sfda.gov.cn [Accessed 2006 Sep 8]

  5. Drug Registration Regulation (SFDA order No.17). Effective 2005 May 1 [online]. Available from URL: http://www.sfda.gov.cn [Accessed 2006 Sep 8]

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Novartis China, 9/F China World Tower I, No.1 Jian Guo Men Wai Avenue, Beijing, 10004, People’s Republic of China

    Michael Humphries & Paul Dai

  2. Novartis Pharma A.G., Basel, Switzerland

    Detlef Niese

Authors
  1. Michael Humphries
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Detlef Niese
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul Dai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Humphries.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Humphries, M., Niese, D. & Dai, P. China as a Growing Research Base for Innovation in Medicines Development. Int J Pharm Med 20, 355–359 (2006). https://doi.org/10.2165/00124363-200620060-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00124363-200620060-00003

Keywords

Search

Navigation